VYNE
VYNE Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$28.56
+0.00%Latest reported
- Last report date
- May 15, 2026
- EPS actual
- -$0.08
- EPS estimate
- -$0.18
- Revenue actual
- $86.0K
- Revenue estimate
- $200.0K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 8
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +40.1%
- Revenue beats (12Q)
- 4
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| May 15, 2026 | -$0.18 | -$0.08 | Beat 55.56% | $86.0K |
| Mar 12, 2026 | -$0.23 | -$0.11 | Beat 50.83% | $130.0K |
| Nov 6, 2025 | -$0.19 | -$0.17 | Beat 10.53% | $169.0K |
| Aug 14, 2025 | -$0.23 | -$0.13 | Beat 43.48% | $69.0K |
| May 8, 2025 | -$0.29 | -$0.20 | Beat 31.03% | $202.0K |
| Mar 6, 2025 | -$0.31 | -$0.28 | Beat 9.68% | $84.0K |
| Nov 7, 2024 | -$0.24 | -$0.29 | Miss -20.83% | $121.0K |
| Aug 14, 2024 | -$0.19 | -$0.22 | Miss -15.79% | $198.0K |
| May 9, 2024 | -$0.24 | -$0.15 | Beat 37.50% | $98.0K |
| Feb 29, 2024 | -$0.50 | -$0.20 | Beat 60.00% | $76.0K |
| Nov 13, 2023 | -$0.76 | -$1.85 | Miss -143.42% | $114.0K |
| Aug 14, 2023 | -$1.99 | -$3.08 | Miss -54.77% | $135.0K |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Aug 13, 2026